Stella Pharma Corp. Hits Day Low of JPY 650 Amid Price Pressure

Stella Pharma Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced significant volatility today, with the stock declining by 8.58% as of April 15, 2026. The stock reached an intraday low of JPY 650.00, reflecting a challenging trading environment. In terms of performance metrics, Stella Pharma's one-day performance starkly contrasts with the Japan Nikkei 225, which saw a modest increase of 0.44%. Over the past week, the stock has decreased by 5.8%, while its one-month performance remains positive at 45.74%. However, the longer-term outlook shows a mixed picture, with a remarkable year-to-date gain of 220.2% compared to the Nikkei's 15.48%. Despite these gains, the company faces significant financial hurdles, including a negative EBITDA of Rs. -55.52 crore and a troubling operating profit decline of 234.76% over the last five years. With a market capitalization of JPY 8,066 million and a return on equity of -6.21%, Stella Pharma Corp. continues to navigate a complex financial landscape.